Baillie Gifford & Co
PBYI icon

Baillie Gifford & Co’s Puma Biotechnology PBYI Stock Holding History

Baillie Gifford & Co’s Portfolio PBYI Stock Details PBYI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-252
Closed -$2K – 513
2021
Q3 		$2K Hold
252
– – ﹤0.01% 489
2021
Q2 		$2K Hold
252
– – ﹤0.01% 469
2021
Q1 		$2K Hold
252
– – ﹤0.01% 443
2020
Q4 		$3K Buy
+252
New +$2.55K ﹤0.01% 423

Other funds holding PBYI

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
EP
Eversept Partners New York $1.93B AUM 160.8% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $27.8B AUM 46.46% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Baillie Gifford & Co's PBYI Position: Q4 2021 in Review

Baillie Gifford & Co sold out of Puma Biotechnology (PBYI) in Q4 2021, closing a stake of 252 shares — an estimated $2K sold.

Baillie Gifford & Co first reported a position in PBYI in Q4 2020 and held it in 4 quarters. The position peaked at $3K in Q4 2020. 102 funds tracked by Wall St. Rank hold PBYI as of Q4 2021.

  • Baillie Gifford & Co reported no remaining Puma Biotechnology position as of Q4 2021 after selling out during the quarter.
  • Baillie Gifford & Co sold 252 Puma Biotechnology shares in Q4 2021, an estimated $2K.
  • Baillie Gifford & Co first reported a position in Puma Biotechnology in Q4 2020 and held it in 4 quarters.
  • Baillie Gifford & Co's Puma Biotechnology position peaked at $3K in Q4 2020.
  • 102 funds tracked by Wall St. Rank held Puma Biotechnology as of Q4 2021.

Based on Baillie Gifford & Co's 13F filing for Q4 2021, filed 20 Jan 2022.